全球活病毒疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計到 2034 年，活病毒疫苗（減毒疫苗）市場規模將從 2025 年的 235 億美元成長至 585.7 億美元，2026 年至 2034 年的複合年成長率為 10.68%。

由於對有效預防感染疾病的免疫接種需求不斷成長，全球活病毒疫苗活病毒疫苗市場正經歷穩定成長。活病毒疫苗含有減毒病原體，能夠誘發強烈的免疫反應，而不會引起嚴重。這些疫苗廣泛用於預防麻疹、腮腺炎、德國德國麻疹和水痘等疾病。

推動這一市場成長的因素包括免疫接種計劃的擴大、疾病預防意識的提高以及政府對舉措措施的大力支持。全球醫療機構正致力於提高疫苗的可及性，以遏制感染疾病的傳播。疫苗研發技術的進步也提高了活病毒疫苗的安全性和有效性。

隨著全球免疫宣傳活動的持續擴大，減毒活病毒疫苗市場預計將進一步成長。針對新發感染疾病疫苗的研發工作將在市場成長中發揮關鍵作用。疫苗儲存和分發系統的改進以及全球醫療衛生基礎設施的完善，也有望為市場的長期擴張提供支援。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球活病毒疫苗市場：依疫苗類型分類

• 市場分析、洞察與預測
• 細菌疫苗
• 病毒疫苗

第5章：全球活病毒疫苗市場：依研發階段分類

• 市場分析、洞察與預測
• 組織培養
• 受精卵
• 活體動物

第6章：全球活病毒疫苗市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物
• 鼻內

第7章：全球活病毒疫苗市場：依年齡層別分類

• 市場分析、洞察與預測
• 兒童
• 成人

第8章：全球活病毒疫苗市場：依適應症分類

• 市場分析、洞察與預測
• 結核
• 麻疹
• 輪狀病毒
• 黃熱病
• 口服脊髓灰質炎疫苗
• 流感
• 其他跡象

第9章：全球活病毒疫苗市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院（公立和私立）
• 專科診所
• 其他最終用戶

第10章 全球活病毒疫苗市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Abbott
  • Bharat Biotech International Limited
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline Plc
  • Haffkine Biopharmaceutical Corporation Limited
  • HBI
  • Merck & Co
  • Novartis Pharmaceuticals Corporation
  • Sanofi
  • Serum Institute Of India Ltd
  • Valneva SE
  • Zydus Group

The Live Attenuated Vaccines Market size is expected to reach USD 58.57 Billion in 2034 from USD 23.50 Billion (2025) growing at a CAGR of 10.68% during 2026-2034.

The global live attenuated vaccines market is experiencing steady growth due to the increasing demand for effective immunization against infectious diseases. Live attenuated vaccines contain weakened forms of pathogens that stimulate a strong immune response without causing severe illness. These vaccines are widely used to prevent diseases such as measles, mumps, rubella, and chickenpox.

The market is driven by growing vaccination programs, rising awareness about disease prevention, and increased government support for immunization initiatives. Healthcare organizations around the world are focusing on improving vaccine accessibility to control the spread of infectious diseases. Technological advancements in vaccine development have also improved the safety and effectiveness of live attenuated vaccines.

In the future, the live attenuated vaccines market is expected to expand as global vaccination campaigns continue to increase. Research efforts aimed at developing vaccines for emerging infectious diseases will play a crucial role in market growth. Improvements in vaccine storage, distribution systems, and global healthcare infrastructure are also expected to support long-term market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

• Bacterial Vaccine
• Viral Vaccine

By Development

• Tissue Culture
• Embryonated Eggs
• Live Animals

By Mode Of Administration

• Oral
• Injectable
• Intranasal

By Age Group

• Pediatric
• Adult

By Indication

• Tuberculosis
• Measles
• Rotavirus
• Yellow Fever
• Oral Polio
• Influenza
• Other Indications

By End-Use

• Hospitals (Public, Private)
• Specialty Clinics
• Other End-Users

COMPANIES PROFILED

• Abbott, Bharat Biotech International Limited, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Haffkine Biopharmaceutical Corporation Limited, HBI, Merck Co, Novartis Pharmaceuticals Corporation, Sanofi, Serum Institute of India Ltd, Valneva SE, Zydus Group
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Vaccine Type
• 4.2. Bacterial Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Viral Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY DEVELOPMENT 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Development
• 5.2. Tissue Culture Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Embryonated Eggs Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Live Animals Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY MODE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Mode Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Intranasal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)

• 8.1. Market Analysis, Insights and Forecast Indication
• 8.2. Tuberculosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.3. Measles Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.4. Rotavirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.5. Yellow Fever Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.6. Oral Polio Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.7. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.8. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY END-USE 2022-2034 (USD MN and Million Doses)

• 9.1. Market Analysis, Insights and Forecast End-use
• 9.2. Hospitals (Public, Private) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 9.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 9.4. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 10. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.2.1 By Vaccine Type
  • 10.2.2 By Development
  • 10.2.3 By Mode Of Administration
  • 10.2.4 By Age Group
  • 10.2.5 By Indication
  • 10.2.6 By End-use
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.3.1 By Vaccine Type
  • 10.3.2 By Development
  • 10.3.3 By Mode Of Administration
  • 10.3.4 By Age Group
  • 10.3.5 By Indication
  • 10.3.6 By End-use
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.4.1 By Vaccine Type
  • 10.4.2 By Development
  • 10.4.3 By Mode Of Administration
  • 10.4.4 By Age Group
  • 10.4.5 By Indication
  • 10.4.6 By End-use
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.5.1 By Vaccine Type
  • 10.5.2 By Development
  • 10.5.3 By Mode Of Administration
  • 10.5.4 By Age Group
  • 10.5.5 By Indication
  • 10.5.6 By End-use
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.6.1 By Vaccine Type
  • 10.6.2 By Development
  • 10.6.3 By Mode Of Administration
  • 10.6.4 By Age Group
  • 10.6.5 By Indication
  • 10.6.6 By End-use
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL LIVE ATTENUATED VACCINES INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Abbott
  • 12.2.2 Bharat Biotech International Limited
  • 12.2.3 Boehringer Ingelheim International GmbH
  • 12.2.4 GlaxoSmithKline Plc
  • 12.2.5 Haffkine Biopharmaceutical Corporation Limited
  • 12.2.6 HBI
  • 12.2.7 Merck & Co
  • 12.2.8 Novartis Pharmaceuticals Corporation
  • 12.2.9 Sanofi
  • 12.2.10 Serum Institute Of India Ltd
  • 12.2.11 Valneva SE
  • 12.2.12 Zydus Group